Royal Bank of Canada’s Aratana Therapeutics, Inc. PETX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q3 | – | Sell |
-710
| Closed | -$4K | – | 7465 |
|
|
2019
Q2 | $4K | Buy |
+710
| New | +$3.19K | ﹤0.01% | 6448 |
|
|
2019
Q1 | – | Sell |
-1,600
| Closed | -$10K | – | 7315 |
|
|
2018
Q4 | $10K | Sell |
1,600
-791
| -33% | -$4.83K | ﹤0.01% | 5915 |
|
|
2018
Q3 | $14K | Buy |
2,391
+691
| +41% | +$3.45K | ﹤0.01% | 5869 |
|
|
2018
Q2 | $7K | Buy |
1,700
+1,085
| +176% | +$5.47K | ﹤0.01% | 5963 |
|
|
2018
Q1 | $3K | Sell |
615
-194
| -24% | -$866 | ﹤0.01% | 6083 |
|
|
2017
Q4 | $4K | Sell |
809
-3,316
| -80% | -$20.3K | ﹤0.01% | 6164 |
|
|
2017
Q3 | $25K | Buy |
4,125
+3,419
| +484% | +$21.6K | ﹤0.01% | 5848 |
|
|
2017
Q2 | $5K | Sell |
706
-1,453
| -67% | -$8.94K | ﹤0.01% | 6071 |
|
|
2017
Q1 | $11K | Buy |
2,159
+1,413
| +189% | +$9.54K | ﹤0.01% | 5941 |
|
|
2016
Q4 | $5K | Buy |
746
+722
| +3,008% | +$5.84K | ﹤0.01% | 6319 |
|
|
2016
Q3 | $0 | Buy |
+24
| New | +$199 | ﹤0.01% | 6693 |
|
|
2016
Q2 | – | Sell |
-4,000
| Closed | -$22K | – | 6646 |
|
|
2016
Q1 | $22K | Buy |
4,000
+1,977
| +98% | +$7.43K | ﹤0.01% | 5453 |
|
|
2015
Q4 | $11K | Buy |
2,023
+906
| +81% | +$5.99K | ﹤0.01% | 5944 |
|
|
2015
Q3 | $9K | Sell |
1,117
-96
| -8% | -$1.63K | ﹤0.01% | 5960 |
|
|
2015
Q2 | $18K | Buy |
+1,213
| New | +$17.5K | ﹤0.01% | 5764 |
|
|
2013
Q4 | – | Sell |
-300
| Closed | -$5K | – | 6278 |
|
|
2013
Q3 | $5K | Buy |
+300
| New | +$3.15K | ﹤0.01% | 5647 |
|
Other funds holding PETX
Royal Bank of Canada's PETX Position: Q3 2019 in Review
Royal Bank of Canada sold out of Aratana Therapeutics, Inc. (PETX) in Q3 2019, closing a stake of 710 shares — an estimated $4K sold.
Royal Bank of Canada first reported a position in PETX in Q3 2013 and held it in 16 quarters. The position peaked at $25K in Q3 2017. 2 funds tracked by Wall St. Rank hold PETX as of Q3 2019.
- Royal Bank of Canada reported no remaining Aratana Therapeutics, Inc. position as of Q3 2019 after selling out during the quarter.
- Royal Bank of Canada sold 710 Aratana Therapeutics, Inc. shares in Q3 2019, an estimated $4K.
- Royal Bank of Canada first reported a position in Aratana Therapeutics, Inc. in Q3 2013 and held it in 16 quarters.
- Royal Bank of Canada's Aratana Therapeutics, Inc. position peaked at $25K in Q3 2017.
- 2 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q3 2019.
Based on Royal Bank of Canada's 13F filing for Q3 2019, filed 14 Nov 2019.